FDA approves Novartis’ Beovu for wet AMD

The FDA has approved Beovu for the treatment of wet age-related macular degeneration, Novartis announced in a press release.
Beovu (brolucizumab-dbll), also known at RTH258, demonstrated noninferiority vs. aflibercept in the phase 3 HAWK and HARRIER clinical trials and is the first FDA-approved anti-VEGF to maintain wet AMD patients on a 3-month dosing interval after a 3-month loading phase, the release said.
“The approval of Beovu delivers on the Novartis commitment to reimagining treatments for patients suffering from serious visual impairment,” Marie-France Tschudin, president of

Full Story →